ANI PHARMACEUTICALS INC
ANIPNASDAQTrading Snapshot
- Day Range
- $73.53 – $74.43
- 52-Week Range
- $70.15 – $99.50
- Volume
- $4.11B
- Avg Volume
- $3.11B
- Shares Outstanding
- 22.7M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $883M
- Last Q Revenue
- $266M
- P/E Ratio
- 15.4
- P/S Ratio
- 1.7x
- EPS (TTM)
- $5.00
- Dividend Yield
- 0.00%
Why Investors Own ANIP
- ✓High-growth profile — revenue up +34.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 42% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ANI PHARMACEUTICALS INC
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90
Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.
ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-08. The following slide deck was published by ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call August 7, 2026 8:00 AM EDTCompany ParticipantsIrina KofflerNikhil Lalwani - President, CEO &...
ANI Pharmaceuticals (NASDAQ:ANIP) Tumbles on Weak Guidance Despite Q2 EPS Beat
ANI Pharma (ANIP) beat Q2 EPS, revenue in line, but shares fell 7.6% as forward outlook trailed estimates. Record quarter led by Cortrophin Gel.